NASDAQ:ARAV - Aravive Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.08 -0.17 (-3.24 %) (As of 02/21/2019 04:21 AM ET)Previous Close$5.25Today's Range$5.02 - $5.2552-Week Range$3.07 - $15.30Volume13,500 shsAverage Volume26,579 shsMarket Capitalization$56.80 millionP/E Ratio4.67Dividend YieldN/ABeta2.35 ProfileDiscussionChartEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. It is developing AVB-S6-500, a GAS6 binding protein and AXL decoy receptor, for the treatment of ovarian cancer, as well as for renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is based in Houston, Texas. Receive ARAV News and Ratings via Email Sign-up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARAV Previous Symbol CUSIPN/A Webaravive.com Phone936-355-1910Debt Debt-to-Equity Ratio0.11 Current Ratio20.21 Quick Ratio20.21Price-To-Earnings Trailing P/E Ratio4.67 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$40,000.00 Price / Sales1,420.11 Cash FlowN/A Price / Cash FlowN/A Book Value$13.86 per share Price / Book0.37Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-84,970,000.00 Net MarginsN/A Return on Equity7.87% Return on Assets6.86%Miscellaneous Employees28 Outstanding Shares11,182,000Market Cap$56.80 million OptionableOptionable Aravive (NASDAQ:ARAV) Frequently Asked Questions What is Aravive's stock symbol? Aravive trades on the NASDAQ under the ticker symbol "ARAV." When is Aravive's next earnings date? Aravive is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Aravive. Has Aravive been receiving favorable news coverage? News articles about ARAV stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aravive earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term. Who are some of Aravive's key competitors? Some companies that are related to Aravive include Aratana Therapeutics (PETX), Cerecor (CERC), MEI Pharma (MEIP), Tocagen (TOCA), Xenon Pharmaceuticals (XENE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), Xeris Pharmaceuticals (XERS), Calithera Biosciences (CALA), CELYAD SA/ADR (CYAD), AcelRx Pharmaceuticals (ACRX), Newron Pharmaceuticals (NWPHF), Aeglea Bio Therapeutics (AGLE), TAIWAN LIPOSOME/S (TLC) and Recro Pharma (REPH). Who are Aravive's key executives? Aravive's management team includes the folowing people: Mr. Jay P. Shepard, Pres, CEO & Director (Age 61)Dr. Jeffrey L. Cleland, Co-Founder (Age 54)Dr. Joshua Silverman Ph.D., Co-FounderMr. Vinay Shah, Chief Financial OfficerMr. Michael Burdick RAC, Sr. VP of Regulatory Affairs Who are Aravive's major shareholders? Aravive's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.58%), Dimensional Fund Advisors LP (1.23%), NF Trinity Capital Hong Kong Ltd (0.37%), Two Sigma Investments LP (0.31%), Geode Capital Management LLC (0.27%) and Two Sigma Advisers LP (0.22%). Company insiders that own Aravive stock include Jay Shepard and Kevin Haas. View Institutional Ownership Trends for Aravive. Which institutional investors are buying Aravive stock? ARAV stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, NF Trinity Capital Hong Kong Ltd, Two Sigma Investments LP, Geode Capital Management LLC, Two Sigma Advisers LP, Millennium Management LLC and D. E. Shaw & Co. Inc.. View Insider Buying and Selling for Aravive. How do I buy shares of Aravive? Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aravive's stock price today? One share of ARAV stock can currently be purchased for approximately $5.08. How big of a company is Aravive? Aravive has a market capitalization of $56.80 million and generates $40,000.00 in revenue each year. Aravive employs 28 workers across the globe. What is Aravive's official website? The official website for Aravive is http://aravive.com. How can I contact Aravive? Aravive's mailing address is Lyondell Basell Tower 1221 McKinney Street Suite 3200, Houston TX, 77010. The company can be reached via phone at 936-355-1910 or via email at [email protected] MarketBeat Community Rating for Aravive (NASDAQ ARAV)Community Ranking: 1.9 out of 5 ()Outperform Votes: 16 (Vote Outperform)Underperform Votes: 26 (Vote Underperform)Total Votes: 42MarketBeat's community ratings are surveys of what our community members think about Aravive and other stocks. Vote "Outperform" if you believe ARAV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2019 by MarketBeat.com StaffFeatured Article: What is a put option?